Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

MR Middleton, O Hamid, AN Shoushtari, FE Meier, TM Bauer, AKS Salama, JM Kirkwood, PA Ascierto, P Lorigan, C Mauch, MM Orloff, TRJ Evans, SE Abdullah, Y Yuan, J Mitchell, JC Hassel

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Issue number16
Publication statusPublished - 1 Jun 2022

Cite this